Nicklaus Children’s Hospital Designated ACR Diagnostic Imaging Center of Excellence

Nicklaus Children’s Hospital has been designated a Diagnostic Imaging Center of Excellence® (DICOE) by the American College of Radiology (ACR).

The DICOE program, which represents the pinnacle of medical imaging care, is an achievement that goes beyond accreditation to recognize best-quality imaging practices and diagnostic care. This includes a comprehensive assessment of the entire medical imaging enterprise, including structure and outcomes. The DICOE designation recognizes excellence at multiple levels — including the professional staff, the technology and the policies and procedures the organization follows — and superior patient care.

“Quality diagnostic imaging is essential to achieving medical excellence,” said Sheryl Selinsky, Executive Director Diagnostic Services. “We are immensely proud of our innovative, child-friendly imaging programs, which contribute immeasurably to our ability to serve the children and families of South Florida and beyond. The Diagnostic Imaging Center of Excellence designation is one more reason why Nicklaus Children’s is the hospital where children matter most.”

“The Department of Radiology has been a national leader in quality improvement for more than 20 years and one of the first in adopting the very stringent ACR metrics. Our goal is to make sure every single patient gets the best diagnostic study because this is going to have a very important impact in their final health outcome,” said L. Santiago Medina, MD, MPH, Associate Director of Radiology and Director of Neuroradiology.

In order to receive this elite distinction, facilities must be accredited by the ACR in all modalities they provide, and in which the ACR offers an accreditation program. Another requirement is to participate in the Dose Index Registry® and General Radiology Improvement Database, as well as Image Wisely® and Image Gently®.

The ACR, founded in 1924, is one of the largest and most influential medical associations in the United States. The ACR devotes its resources to making imaging and radiation therapy safe, effective and accessible to those who need it. Its 38,000 members include radiologists, radiation oncologists, medical physicists, interventional radiologists and nuclear medicine physicians.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”